• Sep 16, 2026

  $376.35+0.19%

• Sep 15, 2026

  $375.65-1.53%

  Comparable listed companies in Biological Products fell 1.01% on average, with 5 of 6 peers down [1].

  • 1Peer group

• Sep 14, 2026

  $381.50+1.10%

  Amgen shares rose 1.10%, alongside comparable biological products companies, which moved +0.89% on average with all 6 rising that day [1].

  • 1Peer group

• Sep 11, 2026

  $377.35-1.34%

  Amgen shares declined after a setback in a clinical trial was reported [1].

  • 1Seeking Alpha

• Sep 10, 2026

  $382.47-2.25%

  Seeking Alpha reported that Amgen raised its full-year 2026 revenue and EPS guidance [1]. Comparable biological products companies moved just -0.05% on average that day, with three of six falling and three rising, so the size of Amgen's decline was not shared by its peers [2].

  • 1Seeking Alpha
  • 2Peer group

• Sep 9, 2026

  $391.27-0.48%

• Sep 8, 2026

  $393.17-10.08%

  Amgen shares fell 10.08% amid concerns that Novartis' pelacarsen Phase 3 trial failure raised read-through worries for Amgen's olpasiran program [1][2]. Comparable biological products companies fell 2.35% on average the same day, with all six names in the group declining, a smaller drop than Amgen's [3]. Trading volume was 3.1x the company's trailing average, with the session ranging between 391.17 and 410.02, about 4.8% of the low [4].

  • 1Seeking Alpha
  • 2Seeking Alpha
  • 3Peer group
  • 4Market data

Closing prices for AMGN. Summaries describe past sessions only and are not advice, a forecast or a recommendation.

Headlines are published by third parties and linked as reported. Amaltash does not endorse or verify them.